Stock Market & Financial Investment News

News Breaks February 15, 2013 10:21 EDT GSK, PFE ViiV Healthcare granted FDA priority review for dolutegravir ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK) and Pfizer (PFE), announced that the U.S. Food and Drug Administration has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection, in combination with other antiretroviral agents, in adults and adolescents. The FDA has assigned dolutegravir a Prescription Drug User Fee Act target date of August 17, 2013. ViiV Healthcare submitted a Marketing Authorisation Application for dolutegravir to the European Medicines Agency on December 17, 2012. News For GSK;PFE From The Last 14 Days Check below for free stories on GSK;PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:25 EDT GSK GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:44 EDT GSK Sachs Associates to host a forum Subscribe for More Information 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information 07:07 EDT GSK Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 16, 2013 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 14, 2013 07:24 EDT GSK EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:25 EDT GSK On The Fly: Closing Wrap Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. 12:20 EDT GSK On The Fly: Midday Wrap Subscribe for More Information 05:44 EDT GSK Elan provides additional information on Elan/Theravance agreement Subscribe for More Information 05:35 EDT GSK Theravance, Elan enter into $1B royalty participation agreement Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.